Before PSM | After PSM | |||||
---|---|---|---|---|---|---|
Variable | Apatinib group (n = 44) | Control group (n = 100) | P | Apatinib group (n = 36) | Control group (n = 72) | P |
Age, years (\(\overline{x}\) ± s) | 52.48 ± 9.96 | 51.76 ± 9.42 | 0.69 | 52.28 ± 8.32 | 53.39 ± 8.32 | 0.515 |
Histology | 0.786 | 0.991 | ||||
Serous | 32 | 77 | 28 | 54 | ||
Endometrioid | 4 | 8 | 3 | 6 | ||
Mucinous | 3 | 9 | 2 | 6 | ||
Clear | 1 | 2 | 1 | 2 | ||
Other | 4 | 4 | 2 | 4 | ||
FIGO Stage | 0.03 | 0.297 | ||||
IIIc | 24 | 79 | 23 | 53 | ||
IV | 20 | 21 | 13 | 19 | ||
ECOG performance status | 0.776 | 0.988 | ||||
0 | 10 | 20 | 8 | 16 | ||
1 | 17 | 45 | 16 | 33 | ||
2 | 17 | 35 | 12 | 23 | ||
Recurrent lesions | 0.033 | 0.637 | ||||
In the pelvic cavity | 11 | 24 | 10 | 17 | ||
Far beyond the pelvis | 33 | 76 | 26 | 55 | ||
Basic illness | 0.592 | 0.779 | ||||
Yes | 17 | 34 | 13 | 28 | ||
No | 27 | 66 | 23 | 44 |